Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27583597 | 0.98 | CYP19A1 (0.49) | CYP19A1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL25397835 | 0.83 | CYP19A1 (0.53) | CYP19A1LMNATSHRCYP2C19 | |
| SCHEMBL17723264 | 0.82 | CYP19A1 (0.49) | CYP19A1ALDH1A1SMN1; SMN2LMNACYP2C19 | |
| SCHEMBL13688430 | 0.82 | CYP19A1 (0.45) | CYP19A1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL9912807 | 0.81 | CYP19A1 (0.51) | CYP19A1ALDH1A1LMNACYP2C19 | |
| SCHEMBL119668 | 0.81 | CYP19A1 (0.51) | CYP19A1ALDH1A1LMNACYP2C19 | |
| SCHEMBL5702555 | 0.81 | CYP19A1 (0.51) | CYP19A1CYP2C19 | |
| SCHEMBL5702559 | 0.81 | CYP19A1 (0.56) | CYP19A1CYP2C19 | |
| SCHEMBL13564182 | 0.79 | CYP19A1 (0.50) | CYP19A1CYP2C19 | |
| SCHEMBL6551405 | 0.79 | CYP19A1 (0.50) | CYP19A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102206247-B | Novel peptides as NS3/NS4a serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2013-03-27 | — | — | CN | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102206247-A | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2011-10-05 | — | — | CN | disclosed |
| CN-101792483-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| EP-1481000-B1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060205672-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| US-7012066-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| CN-1633446-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP (US) | 2005-06-29 | — | — | CN | disclosed |
| US-20040254117-A9 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS LLC | 2004-12-16 | — | — | US | disclosed |
| EP-1481000-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| CN-1498224-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | ���鹫˾ | 2004-05-19 | — | — | CN | disclosed |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SAKSENA ANIL K | 2003-11-20 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205672-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CYP19A1 3220/4885ALDH1A1 2369/4885SMN1; SMN2 3286/4885 |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CYP19A1 3220/4885ALDH1A1 2369/4885SMN1; SMN2 3286/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CYP19A1 3220/4885ALDH1A1 2369/4885SMN1; SMN2 3286/4885 |
| US-20040254117-A9 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CYP19A1 3220/4885ALDH1A1 2369/4885SMN1; SMN2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.